Table 3.
Maternal pharmacokinetic variables (mean ± SE) for each antidepressant type on a subset of SRI-treated women (n = 23).
| Antidepressant | N | AUClast | Cmax | Tpeak | Δ T3-T0 |
|---|---|---|---|---|---|
| (ng/ml) | (h) | (ng/ml·mg) | |||
| Citalopram | 5 | 906 ± 271 | 274 ± 92 | 4.9 ± 0.14 | 3.2 ± 1.0 |
| Fluoxetine† | 3 | 3221 ± 1919 | 613 ± 342 | 5.8 ± 1.0 | 4.3 ± 2.5 |
| Paroxetine | 2 | 125 ± 66 | 24 ± 5.2 | 4.6 ± 0.04 | 0.13 ± 0.21 |
| Sertraline | 2 | 728 ± 256 | 197 ± 105 | 5.3 ± 0.18 | 0.71 ± 0.53 |
| Venlafaxine | 11 | 621 ± 314 | 163 ± 74 | 5.7 ± 0.30 | 0.43 ± 0.13 |
AUClast, area under the curve from T0 (baseline) to the last measured plasma drug concentration (T4); Cmax, maximum (peak) plasma drug concentration (ng/ml); Tpeak, time (hours) from baseline to reach Cmax; Δ T3-T0, change in dose-adjusted plasma concentration (ng/ml·mg) from baseline (T0) to post-dose 3 (T3), representing the change in maternal drug concentration between baseline/pre-dose and post-dose fetal assessments.
†
Fluoxetine not yet reached maximum plasma concentration at time of last blood collection (i.e., T4 estimated as Tpeak). AUClast and Cmax for fluoxetine may be underestimations.